VL
VLDXW
Velo3D, Inc.
No data for this timeframe.
Vol
SEC Reports7
Recent Activity
May 15, 2026
SEC
Velo3D entered into a new at-the-market (ATM) sales agreement with Needham, Cantor Fitzgerald, and Craig-Hallum to sell
8-K, 424B5 — Impact 5/10
May 14, 2026
SEC
Velo3D filed an S-3 registration statement to register 3,000,000 shares of common stock for resale by its CEO's affiliat
S-3 — Impact 5/10
May 12, 2026
SEC
Velo3D reported Q1 2026 revenue of $13.8M, up 48% YoY, and achieved positive gross margin of 17.2% — a key inflection po
8-K — Impact 7/10
Latest Reports
NEUTRAL
8-K, 424B5
5/10
Velo3D entered into a new at-the-market (ATM) sales agreement with Needham, Cantor Fitzgerald, and Craig-Hallum to sell
May 15, 2026
NEUTRAL
S-3
5/10
Velo3D filed an S-3 registration statement to register 3,000,000 shares of common stock for resale by its CEO's affiliat
May 14, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
7 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 2 mixed, 3 neutral. Avg impact: 5.3/10.
NEUTRAL
8-K, 424B5
5/10
Velo3D entered into a new at-the-market (ATM) sales agreement with Needham, Cantor Fitzgerald, and C
May 15, 2026
NEUTRAL
S-3
5/10
Velo3D filed an S-3 registration statement to register 3,000,000 shares of common stock for resale b
May 14, 2026
BULLISH
8-K
7/10
Velo3D reported Q1 2026 revenue of $13.8M, up 48% YoY, and achieved positive gross margin of 17.2% —
May 12, 2026
BEARISH
424B5
6/10
Velo3D is offering 3,571,428 shares of common stock at $14.00 per share, a 19.4% discount to the las
Apr 27, 2026
NEUTRAL
DEFA14A
2/10
Velo3D, Inc. filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, which include
Apr 27, 2026
MIXED
EFFECT
6/10
Velo3D's $500 million universal shelf registration has become effective, allowing the company to iss
Apr 9, 2026
MIXED
S-3
6/10
Velo3D filed a $500 million universal shelf registration, allowing future issuance of common stock,
Apr 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 36.0% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.1B | 39.4% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.1B | 50.0% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.